FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.4.11  |  FHIR Version n/a  User: [n/a]

Resource ValueSet/FHIR Server from package us.nlm.vsac#0.21.0 (125 ms)

Package us.nlm.vsac
Type ValueSet
Id Id
FHIR Version R4
Source http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1110.50/expansion
Url http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.50
Version 20220219
Status active
Date 2022-02-19T01:06:51-05:00
Name RivaroxabanForVTEProphylaxis
Title Rivaroxaban for VTE Prophylaxis
Experimental False
Realm us
Authority hl7
Purpose (Clinical Focus: The purpose of this value set is to represent concepts for medications of rivaroxaban indicated for venous thromboembolism (VTE) prophylaxis and treatment.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for oral forms of rivaroxaban.),(Exclusion Criteria: No exclusions.)

Resources that use this resource

ValueSet
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204 VTE Prophylaxis

Resources that this resource uses

CodeSystem
http://www.nlm.nih.gov/research/umls/rxnorm RxNorm
http://www.nlm.nih.gov/research/umls/rxnorm RxNorm


Source

{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1110.50",
  "meta" : {
    "versionId" : "20",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail" : {
        "name" : "TJC EH Author"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-keyWord",
      "valueString" : "VTE-01,VTE-02"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-01-31"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-02-19"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.50",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1110.50"
    }
  ],
  "version" : "20220219",
  "name" : "RivaroxabanForVTEProphylaxis",
  "title" : "Rivaroxaban for VTE Prophylaxis",
  "status" : "active",
  "experimental" : false,
  "date" : "2022-02-19T01:06:51-05:00",
  "publisher" : "TJC EH Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for medications of rivaroxaban indicated for venous thromboembolism (VTE) prophylaxis and treatment.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for oral forms of rivaroxaban.),(Exclusion Criteria: No exclusions.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "1114198",
            "display" : "rivaroxaban 10 MG Oral Tablet"
          },
          {
            "code" : "1232082",
            "display" : "rivaroxaban 15 MG Oral Tablet"
          },
          {
            "code" : "1232086",
            "display" : "rivaroxaban 20 MG Oral Tablet"
          },
          {
            "code" : "1549682",
            "display" : "{42 (rivaroxaban 15 MG Oral Tablet) / 9 (rivaroxaban 20 MG Oral Tablet) } Pack"
          },
          {
            "code" : "2059015",
            "display" : "rivaroxaban 2.5 MG Oral Tablet"
          },
          {
            "code" : "2588062",
            "display" : "rivaroxaban 155 MG Granules for Oral Suspension"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:44524ad3-2e84-4b5b-9203-bfe972589b41",
    "timestamp" : "2024-12-10T06:13:42-05:00",
    "total" : 6,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "1114198",
        "display" : "rivaroxaban 10 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "1232082",
        "display" : "rivaroxaban 15 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "1232086",
        "display" : "rivaroxaban 20 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "1549682",
        "display" : "{42 (rivaroxaban 15 MG Oral Tablet) / 9 (rivaroxaban 20 MG Oral Tablet) } Pack"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "2059015",
        "display" : "rivaroxaban 2.5 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11042024",
        "code" : "2588062",
        "display" : "rivaroxaban 1 MG/ML Oral Suspension"
      }
    ]
  },
  "text" : {
  }
}

XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.